Clinical Trial Update: One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of JCXH-211 intratumoral injection in combination with an anti-PD-1 antibody in patients with malignant s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumors

Drugs mentioned

• Anti-PD-1 antibody
• JCXH-211

Snippet

Sponsor: Immorna Biotherapeutics, Inc. | Conditions: Malignant Solid Tumors | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING